

Draft Agenda (9 October 2024)

	Saturday, 2 November
9:00 am	Registration/Coffee
9:30	Welcome
	KDA President
9:45	KDA Keynote Address
	Ms. Susanne Waite, Founder and President Emeritus
10:00	The Ten Things I've Learned in My 25 Years with KD
	Ed Meyertholen, PhD
10:30	The KD Family: Genetics, Testing, and the Implications
	Alice Shindler, Lead Genetics Counselor, NIH/NINDS
10:55	Break
11:15	What We Are Learning About Carriers
	Abdullah AlQahtani, MD, MPH
44.40	Johns Hopkins University
11:40	What's New in Mobility Devices?
	Jim Kissling, President, AutoFarm Mobility
12.00	Note: Mobility devices will be on display in Salon 4. Lunch
12:00 pm 1:30	How to Increase the Impact of the KDA
1.50	Terry Thompson, KDA President
	Lew Myers, KDA Fundraising Advisor
1:45	KDA Umbrella Organizations: Value to KD Patients
1.45	Brian Lin, MDA,
	Alli Ward, NORD
2:10	An Emotional Roadmap for the Journey with Kennedy's Disease
	Dr. John Weaver, Psy.D.
	Owner, Stress Management & Mental Health Clinics
3:00	Break
3:30	Breakout Sessions
	KD Men, Carriers, Spouses/Caregivers (In-person only)
5:00	Conference Sessions End for the Day
6:00	Reception and Beginning of Silent Auction
7:00	Dinner (included with registration)
	Ballroom D
8:00	Live auction and completion of silent auction
	-

	Sunday, 3 November
	Note: Time Change to EST
7:30 am	Breakfast Buffet
8:20	Welcome to Day 2 and Announcements
	KDA President
8:30	Tips and Tricks for KD Men, with Q&A
	Moderator: Jameson Parker, KDA Vice President
	KDA Board Members
9:00	Tips from an Occupational Therapist
	Kathleen Farrell, OTR/L, Occupational Therapist, NIH
9:25	NIH Natural History Study: Results and Implications
0.50	Chris Grunseich, MD, NIH/NINDS
9:50	Break
10:20	Advice from a KD Clinician, with Q&A
	Tahseen Mozaffar, MD, University of California, Irvine
11:00	With NIH clinicians Angela Kokkinis, Chris Grunseich, Abdullah AlQahtani A Primer on KD Research
11.00	Ed Meyertholen, PhD
11:30 pm	Lunch
1: 00	Keynote Address for Research
1. 00	Kurt Fischbeck, MD, NIH (emeritus)
	Al La Spada, MD, PhD, University of California, Irvine
1:20	Unexpected Prevalence of KD Gene Mutation
1.20	Matteo Zanovello, University College, London
1:40	Clinical Trials Update
	Overview: Chris Grunseich, MD, NIH/NINDS
	Vissia Viglietta, MD, PhD, Nido Biosciences – <i>Nido-361 Update</i>
	Andy Chen, PhD, AnnJi Pharmaceutical Co.
	Gianni Soraru, MD, University of Padua – <i>Update on Clenbuterol trial</i>
	Milan Barnes, NIH – Use of wearable sensors in SBMA
2:30	Break
3:00	Reports from KDA Grant Recipients
	 Carlo Rinaldi, MA, MD, PhD, Oxford University – Harnessing polyQ AR
	transcriptional activity to advance a gene therapy strategy in the SBMA clinic
	Shinichiro Yamada, MD, PhD, Nagoya University – Pathophysiology and
	development of symptomatic therapy for cold paresis in SBMA
	 Alyson Sujkowski, PhD, Wayne State University – Using drosophila exercise for therapeutic discovery in Kennedy's Disease
	 Kerri Schellenberg, MD, University of Saskatchewan – Clinical characteristics
	and prevalence of KD in the indigenous populations of western Canada
	• Silvia Fenu, MD, Besta Institute – Connecting SBMA national registries and
	databases
4:00	Research Summary and Q&A, with senior researchers and lab heads
	Moderator: Diane Merry, PhD, Thomas Jefferson University
5:00	Conference Ends for the Day

	Monday, 4 November
7:30 am	Breakfast Buffet
	Foyer
8:20	Conference Updates and Introduction of Research Panels
	KDA President Panel Coordinator Andry Lieberman, MD, PhD, University of Michigan
8:30	Panel Coordinator: Andy Lieberman, MD, PhD, University of Michigan Panel 1: Disease Mechanisms
0.50	Moderator: Andy Lieberman, MD, PhD, University of Michigan
	• Janghoo Lim, PhD, Yale University – <i>Protein Homeostasis in the</i>
	Pathogenesis of SBMA
	 David Luong, LaSpada Lab, UC Irvine – Delineating novel pathways of
	motor neuron demise in SBMA
	• Caterina Marchioretti, PhD, University of Padua – <i>From molecular</i>
	pathogenesis to pharmacological intervention targeting skeletal muscle
	Diane Merry, PhD, Thomas Jefferson University Helen Minarda, PhD, Cose Western Progress, Stern cell modeling of
	 Helen Miranda, PhD, Case Western Reserve – Stem cell modeling of SBMA
	 Heather Montie, PhD, Philadelphia College of Osteopathic Medicine –
	Does CD38 disrupt skeletal muscle function in KD?
	• Gianni Soraru, MD, University of Padua - <i>Hearing function in KD: a</i>
	case control study from a tertiary referral center
10:15	Break
10:45	Panel 2: Translational Targets
	Moderator: Diane Merry, PhD, Thomas Jefferson University
	 Riccardo Cristofani, PhD, University of Milan – A new degradative pathway for AR: the role of chaperone-mediated autophagy
	 Ramesh Narayanan, PhD, University of Tennessee – <i>Update on the</i>
	preclinical development of AR N-Terminus domain binding degrader
	ONCT-505 for the treatment of KD
	 Agamjot Sangotra and Andy Lieberman, University of Michigan –
	Harnessing protein quality control to degrade polyglutamine AR in
	SBMA
	 Ambra Speciale, Oxford University – RNA editing dysregulation in SBMA: molecular mechanisms and therapeutic implications
	 Brad Turner, PhD, and Jack Juan, University of Melbourne, Florey
	Institute – Developing a brain-penetrating antisense treatment approach
	for SBMA
12:00 pm	Conference Wrap-up, with Q&A
40.00	KDA President
12:30	Conference Ends for All but Researchers
1:00	Researcher Luncheon and Discussion

3:00

End of KDA 2024 Conference